Antifibrotic properties

"Antifibrotic properties" refers to the ability of a substance, molecule, or therapeutic intervention to prevent, slow, or reverse **fibrosis**—the pathological accumulation of extracellular matrix and scar tissue in organs such as lung, liver, heart, or kidneys. Fibrosis is primarily driven by the activation, proliferation, and differentiation of fibroblasts and related cells, leading to excessive deposition of collagens and other matrix components. Numerous drugs and biological targets are being explored to achieve antifibrotic effects, most notably by inhibiting pathways such as TGF-β signaling, lysophosphatidic acid receptors, angiotensin signaling, and peroxisome proliferator-activated receptor (PPAR) pathways[1][2][3][4][6]. Antifibrotic therapies are primarily developed for diseases including idiopathic pulmonary fibrosis (IPF), nonalcoholic steatohepatitis (NASH), liver cirrhosis, renal fibrosis, and cardiac fibrosis[1][3][5][7]. Two drugs, **pirfenidone** and **nintedanib**, are approved for IPF and recognized for their antifibrotic effects[1][5][7]. However, "antifibrotic properties" itself is not a single therapeutic target, molecule, or receptor; instead, it is a characteristic of diverse compounds or molecular pathways engaged to inhibit fibrosis in disease states. To search for structured information, it is necessary to specify a particular molecule, receptor, or pathway associated with antifibrotic activity, such as "Transforming growth factor beta receptor", "Peroxisome proliferator-activated receptor alpha", or "Lysophosphatidic acid receptor 1"[2][3][6][1].

Other names

anti-fibrotic activityanti-fibrotic effectfibrosis inhibition